Biomarker Discovery
Building biomarker systems to measure senescence burden, track response, and improve trial design.
Key problem: There is no universal standardized senescence marker panel across tissues, which slows translation and endpoint selection.
Focus Areas
- Cross-tissue biomarker panel development for preclinical and early clinical programs.
- Assays for response prediction and treatment monitoring.
- Integration of molecular markers with functional outcomes.
Business Relevance
- Enables stronger partner packages for licensing.
- Supports service revenue through biomarker validation projects.
- Reduces development risk through earlier signal detection.